Barclays (LON:BARC) analyst Balaji Prasad maintained a Buy rating on Viatris on Friday, setting a price target of $27, which is approximately 49.09% above the present share price of $18.11.
Prasad expects Viatris to post earnings per share (EPS) of $0.36 for the fourth quarter of 2020.
The current consensus among 4 TipRanks analysts is for a Moderate Buy rating of shares in Viatris, with an average price target of $23.5.
The analysts price targets range from a high of $25 to a low of $22.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $2.97 billion and a net profit of $370.3 million. The company's market cap is $9.81 billion.
According to TipRanks.com, Barclays analyst Balaji Prasad is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 7.7% and a 54.26% success rate.
Registered in the Netherlands, Mylan (NASDAQ:VTRS) is a leading generic drugmaker, with roughly 55 manufacturing and research and development facilities. Although Mylan was formed in 1961, its position as the second- largest generic company was largely attributable to the acquisition of Matrix Laboratories and generics business of Germany-based Merck KGaA. Mylan has a portfolio of more than 7,500 generic, specialty, and over-the-counter active ingredients and medicines and is predominantly recognized for manufacturing the EpiPen (treatment for anaphylaxis), which was acquired through the Merck KGaA transaction. Unlike its peers, the company has made the most progress on the biosimilar front.